Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed colorectal adenocarcinoma meeting the following criteria:~  * Exclusively peritoneal carcinomatosis (no other metastases)~ * Resectable disease~* Primary tumor may be same in the same location as another synchronous carcinomatosis~* Patients with metastatic disease who have been in complete remission for more than 1 year are eligible regardless of prior chemotherapy~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hemoglobin ≥ 10 g/dL~* Bilirubin ≤ 1.25 times upper limit of normal (ULN)~* AST and ALT ≤ 3 times ULN~* Creatinine ≤ 1.25 times ULN~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No allergy, hypersensitivity, or other contraindication to leucovorin calcium, oxaliplatin, or fluorouracil~* No other noncancerous disease that would preclude study therapy~* Good nutritional status~* No sensitive peripheral neuropathy with functional impairment~* No hypoplasia or bone marrow failure~* No clinically significant cardiovascular disease within the past year (e.g., unstable angina or myocardial infarction)~* No other cancer within the past 5 years unless in complete remission with the exception of cervical carcinoma in situ or basal cell cancer~* No patients deprived of liberty or under supervision~* No psychological, social, familial, or geographical reasons prohibiting follow-up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 1 year since prior adjuvant chemotherapy, including prior therapy with oxaliplatin and/or cetuximab~* No prophylactic phenytoin (Dihydan®, Dilantin®)~* No prior yellow fever vaccine~* More than 1 month since participation in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy + Cetuximab (Type: EXPERIMENTAL): Surgery + Chemotherapy + Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).